The Harvard Business Review (HBR) has selected Pascal Soriot among the Top 100 Best Performing CEOs in the world for 2019, and one of only three CEOs from a biopharmaceutical company.
HBR’s ranking is based on a CEO’s financial performance as well as environmental, social, and governance (ESG) ratings. Unlike rankings that are based on subjective evaluations or short-term metrics, the CEO 100 list relies on objective performance measures over a chief executive’s entire tenure, according to HBR.
“This recognition goes to the more than 60,000 AstraZeneca employees who come to work every day to follow the science and transform medicine. It speaks volumes about the commitment of our people to bring innovative medicines to patients whether they work in our labs, in the field, our manufacturing sites or our many other locations around the world,” sais Pascal Soirot, CEO, AstraZeneca.
“Pascal’s leadership and strategic thinking have been instrumental in transforming AstraZeneca in recent years. This award reflects not only his dedication, expertise and integrity but also that of the many thousands of colleagues across AstraZeneca who have delivered exceptional results for the millions of patients we serve around the world. It is a great honour to see AstraZeneca recognised for its work in one of the world’s most respected publications,” said Leif Johansson, Chairman of the Board of AstraZeneca.
Pascal Soriot is ranked number 77 out of 100 CEOs in the HBR report.